Skip to main content

Table 1 Summary result of therapeutic efficacy study in six sentinel sites in Myanmar (2009–2013)

From: Clinical and molecular surveillance of artemisinin resistant falciparum malaria in Myanmar (2009–2013)

Description

Kawthaung

Myawaddy

TBZ

Shwegyin

Rakhine

Magway

Year

2009

2009

2010

2012

2013

2010

2012

2013

2010

2009

2009

2012

2013

2010

2010

2012

Drug

DP

AL

AL

AL

AM

AL

AL

DP

DP

DP

AL

AL

DP

AL

DP

AL

Recruited cases

80

80

85

58

48

75

59

68

83

72

86

51

39

81

80

115

Treatment failure

4

6

5

0

0

4

2

3

2

0

2

3

1

3

1

0

LFU

0

0

1

0

0

1

0

0

5

0

0

1

0

0

0

0

Day 1 parasite positivity (n, %)

76 (95.0)

52 (65.0)

75 (89.3)

47 (81.0)

40 (83.3)

61 (82.4)

39 (66.1)

52 (76.5)

76 (97.4)

51 (70.8)

72 (83.7)

9 (18.0)

11 (28.2)

31 (38.3)

39 (48.8)

81 (70.4)

Day 2 parasite positivity (n, %)

54 (67.5)

30 (37.5)

38 (45.2)

12 (20.7)

23 (47.9)

22 (29.7)

15 (25.4)

16 (23.5)

44 (56.4)

15 (20.8)

30 (34.9)

2 (4.0)

1 (2.6)

1 (1.2)

3 (3.8)

31 (27.0)

Day 3 parasite positivity (n, %)

15 (18.7)

5 (6.3)

7 (8.3)

7 (12.1)

5 (10.4)

3 (4.1)

8 (13.6)

4 (5.9)

17 (20.5)

3 (4.2)

8 (9.3)

3 (6.0)

5 (12.8)

0 (0.0)

0 (0.0)

0 (0.0)

ACPR (n, %)

76 (95.0)

74 (92.5)

79 (94.0)

58 (100.0)

48 (100.0)

70 (94.6)

57 (96.6)

65 (95.6)

76 (97.4)

72 (100.0)

84 (97.7)

47 (94.0)

38 (97.4)

78 (96.3)

79 (98.7)

115 (100.0)

Recrudescence

2

6

2

0

0

1

2

3

1

0

0

1

0

0

0

0

Reinfection

1

0

2

0

0

2

0

0

1

0

1

1

1

3

1

0

  1. TBZ Thanbyuzayat, DP dihydroartemisinin–piperaquine, AL artemether–lumefantrine, LFU loss to follow-up, ACPR adequate clinical and parasitological response, ETF early treatment failure, LCF late clinical failure, LPF late parasitological failure